Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06275373 · ClinicalTrials.gov registry record
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
A clinical trial of Thyroid Eye Disease and Graves Disease, sponsored by Walter Reed National Military Medical Center.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06275373: Recruiting study of Thyroid Eye Disease and Graves Disease, sponsored by Walter Reed National Military Medical Center.
NCT06275373 is a study of Thyroid Eye Disease and Graves Disease that is actively recruiting participants, run by Walter Reed National Military Medical Center. The registered enrollment target is 100 participants, roughly in line with the 100-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06275373, a study of Thyroid Eye Disease and Graves Disease, is actively recruiting participants, sponsored by Walter Reed National Military Medical Center.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).
Primary Outcome
CAS scoring (1 to 10)
Conditions Studied
Interventions
- DRUG Teprotumumab Injection [Tepezza]
Study Locations (1)
Maryland
- Walter Reed National Military Medical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2027-12-12 |
What NCT06275373 shows while recruiting
NCT06275373 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 100-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target.
The record links to 3 conditions, with Thyroid Eye Disease appearing as the primary indexed condition, and to 1 intervention - of which Teprotumumab Injection [Tepezza] is the first listed.
NCT06275373 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06275373 about?
NCT06275373 is a clinical study titled "The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction". This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment...
What is the current status of trial NCT06275373?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2021-05-12. Estimated completion is 2027-12-12.
What conditions does trial NCT06275373 study?
This clinical trial studies the following conditions: Thyroid Eye Disease, Graves Disease, Graves Ophthalmopathy.
What interventions are being tested in trial NCT06275373?
The interventions under investigation include: Teprotumumab Injection [Tepezza] (DRUG).
Who is sponsoring clinical trial NCT06275373?
This trial is sponsored by Walter Reed National Military Medical Center, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06275373 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06275373's enrollment target sits among peer trials
100 7th of 15 higher than 8 of 15 other Thyroid Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
RECRUITING · Phase 1
-
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
RECRUITING · Phase 2
-
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
RECRUITING · Phase 1
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI